Recent Updates
Recently added Catalysts
XFOR Positive Sentiment

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

Key Takeaway: X4 Pharmaceuticals announced that its management team will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference. The event is scheduled for Thursday, September 10, 2026, at 9:30 a.m. ET. Investors can access the live and archived webcast via the company website. The firm focuses on rare hematology diseases and commercializes mavorixafor.
Price reaction · baseline $3.505 (2026-09-08 close) · hit pre-market · clean, no other XFOR news in the window
day 0 close · peak
+2.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • X4 Pharmaceuticals is actively engaging with investors.
  • Participation in a reputable healthcare conference enhances visibility.
  • Focus on rare hematology diseases highlights a niche market.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+98%
120-day peak, hindsight
Typical move
8.8%
average across 2 past catalysts
Cash runway
~27 mo
Minimal dilution risk
Lead asset
Mavorixafor
Phase 3 · Neutropenia

Full Press Release Details

BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10, 2026 at 9:30 a.m. ET.
A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations .
About X4 Pharmaceuticals
X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI® in its first indication. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com .
X4 Investor Contact: Remy Bernarda Jenny Kobin IR Advisory Solutions ir@x4pharma.com
Source: X4 Pharmaceuticals, Inc.

Frequently Asked Questions

What is the purpose of the fireside chat?

The fireside chat aims to discuss X4 Pharmaceuticals' initiatives in rare hematology diseases.

When will the conference take place?

The 2026 Wells Fargo Healthcare Conference is scheduled for Thursday, September.

Who will represent X4 Pharmaceuticals at the event?

Management from X4 Pharmaceuticals will participate in the fireside chat.

Why is this conference significant for X4 Pharmaceuticals?

It enhances visibility and fosters investor relations in a niche market.

Last updated: Sep 9, 2026